Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. 

It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms.


ICYMI Leader Board

Stocks highlighted in green have made market-moving announcements (click headings to sort).

Wordpress Table Plugin


Blaze Minerals (ASX:BLZ) is buying the 340sqkm greenfields North Spirit lithium project in Ontario which is 30km along strike from the 50Mt PAK and Spark projects, where owner Frontier Lithium (TSX.V:FL) recently pulled up an eyewatering 398m @ 1.88% Li2O1, including 23m @ 3.12% Li2O2 in one drillhole.

It is also in the same neighbourhood as recently listed Patriot Lithium (ASX:PAT).

The acquisition will cost BLZ an initial $100,000 cash and $550,000 worth of shares (55m shares at 1c). The company will then pay an additional $2.65m cash and $5.95m shares in staged payments right up to the release of a mining feasibility study.

The vendor will also retain a 2% net smelter royalty (NSR) should the project enter production.

Far East Gold (ASX:FEG) has uncovered bonanza gold grades south of the Aloe Eumpeuk prospect at the  Woyla project.

Sampling of the 1-3m wide veins — which returned grades up to 28.4 g/t Au, 8.5 g/t Ag and 58 g/t Au, 27.3 g/t Ag — indicates the potential for Aloe Eumpeuk to link up with the Aloe Rek prospect to the southwest, “significantly increasing the 13km defined strike length of the Woyla project’s vein system”.

High-Tech Metals (ASX:HTM) has completed successful ground magnetic and electromagnetic surveys at its Werner Lake Cobalt Project to identify high priority electrical conductors and/or magnetic anomalies for follow-up drilling. 

MTM Critical Metals (ASX:MTM) has kicked off maiden diamond drilling at its Pomme rare earths-niobium project in Canada, and will look to extend and delineate mineralisation identified by historical drilling which returned intercepts of 508.3m grading 0.43% total rare earth oxides (TREO), 413 parts per million (ppm) niobium oxide and 1.48% phosphate from 73.7m.

And the US FDA has accepted Mesoblast’s (ASX:MSB) filing of the Biologics License Application (BLA) for remestemcel-L, in the treatment of children with steroid-refractory graft versus host disease (SR-aGVHD has set a Pre). 

The regulator has now set a Prescription Drug User Fee Act (PDUFA) goal date of August 2.

At Stockhead we tell it like it is. While MTM Critical Metals is a Stockhead advertiser, it did not sponsor this article.